Has Theresa Tran, MD received payments from drug or device companies?

Yes. Drug and device makers reported $738 in general payments to Theresa Tran, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Theresa Tran, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Theresa Tran, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Theresa Tran, MD

Otolaryngology · New York, NYNPI 1578564407

Payments from drug & device makers

$738in general payments, 2019–2025

Across 29 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optinose US, Inc.$238
Johnson & Johnson$134
Biotissue Holdings Inc.$104
Jazz Pharmaceuticals Inc.$80
GSK$72
Inspire Medical Systems, Inc.$43
plus $66 from 3 others

What the payments were for

Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optinose US, Inc.	14	$238
Johnson & Johnson(2 entities)	2	$134
Biotissue Holdings Inc.	1	$104
Jazz Pharmaceuticals Inc.	4	$80
GSK	2	$72
Inspire Medical Systems, Inc.	2	$43
Davol Inc.	2	$32
Ambu Inc.	1	$20
Tactile Systems Technology Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738 in reported general payments places this provider in the 40th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$33,018

Medicare patients

105

Services billed

208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluticasone Propionate	45	$612
Omeprazole	23	$250

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New York

Anthony DelsignoreNew York$966K
Roheen RaithathaNew York$882K
Dennis KrausNew York$524K
Ashutosh KackerNew York$387K
Lawrence LustigNew York$383K
Brett MilesNew York$368K
Alfred Marc IloretaNew York$342K
Hae-Ok KimNew York$104K
Gregory LevitinNew York$48K
David KaufmanNew York$42K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →